Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Inhibikase Therapeutics (IKT) over the last 4 years, with Q3 2025 value amounting to $23688.0.

  • Inhibikase Therapeutics' Depreciation & Amortization (CF) rose 26065.77% to $23688.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $67066.0, marking a year-over-year increase of 15526.59%. This contributed to the annual value of $26272.0 for FY2024, which is 8519.04% down from last year.
  • Latest data reveals that Inhibikase Therapeutics reported Depreciation & Amortization (CF) of $23688.0 as of Q3 2025, which was up 26065.77% from $24157.0 recorded in Q2 2025.
  • In the past 5 years, Inhibikase Therapeutics' Depreciation & Amortization (CF) ranged from a high of $159204.0 in Q2 2023 and a low of $1681.0 during Q3 2022
  • Over the past 4 years, Inhibikase Therapeutics' median Depreciation & Amortization (CF) value was $6568.0 (recorded in 2023), while the average stood at $20836.7.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Depreciation & Amortization (CF) soared by 29071.98% in 2023, and later plummeted by 9587.38% in 2024.
  • Over the past 4 years, Inhibikase Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $5042.0 in 2022, then skyrocketed by 30.27% to $6568.0 in 2023, then decreased by 0.02% to $6567.0 in 2024, then skyrocketed by 260.71% to $23688.0 in 2025.
  • Its last three reported values are $23688.0 in Q3 2025, $24157.0 for Q2 2025, and $12654.0 during Q1 2025.